|Bid||38.25 x 800|
|Ask||42.70 x 1100|
|Day's Range||41.97 - 42.67|
|52 Week Range||37.67 - 45.62|
|Beta (3Y Monthly)||0.38|
|PE Ratio (TTM)||21.79|
|Forward Dividend & Yield||1.74 (3.98%)|
|1y Target Est||52.00|
- Pivotal Phase 3 data evaluated isatuximab (anti-CD38) in combination with pomalidomide/dexamethasone in prolonging progression-free survival in relapsed/refractory multiple myeloma - Longer-term Libtayo® ...
Working with partner Happify Health, the French drugmaker is studying a potential digital therapy for patients with depression and multiple sclerosis. “The regulatory pathway has really become much more amenable, and we know for certain diseases, a digital therapeutic can actually be very effective,” Chief Digital Officer Ameet Nathwani said in an interview at Sanofi’s headquarters in Paris. Drugmakers are looking increasingly at apps and other software tools that are proven in trials, reviewed by regulators and prescribed by doctors to treat a range of diseases.
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
BRIDGEWATER, N.J., May 8, 2019 /PRNewswire/ -- For the second consecutive year, Sanofi has been named to DiversityInc's 2019 Top 50 Companies for Diversity. The DiversityInc Top 50 list recognizes the nation's top companies for diversity and inclusion management. Sanofi has also been named to two of DiversityInc's Specialty Lists – Top Companies for LGBT Employees and Top Companies for Philanthropy.
GUILDFORD, England , May 8, 2019 /PRNewswire/ -- FOR UK MEDIA ONLY The first biologic licensed in the EU for severe asthma with type 2 inflammation, as characterised by raised blood eosinophils and/or ...
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday.Source: Shutterstock Regeneron Pharmaceuticals (NASDAQ:REGN) reported earnings per share of $4.45 for the first quarter of the year. This is a drop from the company's earnings per share of $4.67 from the first quarter of 2018. It was also a major blow to REGN stock by coming in short of Wall Street's earnings per share estimate of $5.46 for the period.The Regeneron Pharmaceuticals earnings report for the first quarter of 2019 also includes net income of $461 million. That's down from the company's net income of $478 million reported in the same period of the year prior.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOperating income reported by Regeneron Pharmaceuticals in its earnings report for the first quarter of the year comes in at $480 million. This is a decrease from the company's operating income of $567 million reported in the first quarter of the previous year.Regeneron Pharmaceuticals earnings for the first quarter of 2019 has revenue coming in at $1.71 billion. This is better than the company's revenue of $1.51 billion reported during the same time last year. However, it was bad news for REGN stock by missing analysts' revenue estimate of $1.76 billion for the quarter. * 7 Strong Buy Stocks That Tick All the Boxes Regeneron Pharmaceuticals notes that it is now expecting lower reimbursement from Sanofi (NASDAQ:SNY) for 2019. This has it expecting reimbursement between $500 million and $535 million. It was previously expecting this to be in the range of $510 million to $560 million.REGN stock was down 5% as of Tuesday morning. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Strong Buy Stocks That Tick All the Boxes * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund * 5 Tech ETFs to Plug In to Big Profits As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss appeared first on InvestorPlace.
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
Esperion popped Monday after the Food and Drug Administration accepted its applications for a pair of cholesterol treatments called bempedoic acid and bempedoic acid plus ezetimibe.
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.
Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Diabetes franchise revenuesIn the first quarter, Sanofi’s (SNY) Diabetes franchise reported net sales of 1.29 billion euros, a YoY decline of 6.9% on a CER
Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Immunology revenuesIn the first quarter, Sanofi’s (SNY) Immunology franchise reported net sales of 359 million euros, a YoY rise of 186.3% on a CER (constant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Rare blood disorder revenues In the first quarter, Sanofi’s Rare Blood Disorder franchise reported net sales of 274 million euros, a YoY rise of 296.9% on a CER
BRIDGEWATER, N.J., May 1, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Dengvaxia® (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection. Dengvaxia is the first and only vaccine approved for protection against dengue in endemic areas of the U.S. "Dengue is endemic and prone to outbreaks in several U.S. territories, including Puerto Rico, the U.S. Virgin Islands and American Samoa.
Is Sanofi an Attractive Pick after First-Quarter Results?(Continued from Prior Part)Oncology revenuesIn the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange